“Peptides” have become a hot topic in the wellness industry and on social media. Interest recently spiked after HHS Secretary RFK Jr. announced a push to loosen federal restrictions on a group of peptides, making it easier for compounding pharmacies to prepare them. Most of these peptides are currently labeled “research use only” and cannot legally be prescribed.
Peptides are compounds containing a peptide bond. They can be natural or synthetic, and taken orally or by injection. Some classes of peptides—like GLP-1 receptor agonists, which target specific receptors—have real support in the scientific and medical literature. But social media has also fueled a growing set of claims about many other peptide compounds, promoting them for uses like weight loss, “anti-aging,” and muscle growth and recovery. Most of these claims rest on theoretical mechanisms, not human clinical trial data.
This raises safety concerns: many peptides sold online are from the grey market and are labeled “for research use only,” yet are being bought and used by the general public.
Our brief defines peptides, explains the technological advances that have driven this class of therapeutics, examines specific peptides of interest, and reviews the evidence behind their use. It also discusses the regulatory implications and the lack of approval for emerging peptides. You can download it here.
Contributors (listed alphabetically): Leigh Baxt, PhD; Catlin Dow, PhD; Irini Hadjisava, PhD; Kevin Klatt, PhD, RD; Edward Nirenberg; Jess Steier, DrPH
This article originally appeared on the Substack of The Evidence Collective — a group that bridges the gap between scientific knowledge and the public through clear, accessible, and empathetic communication so that everyone has the best evidence and clear guidance to make personal decisions. It is reposted with their permission.
